Obesity biotech Aardvark files for IPO to advance oral drug
Aardvark Therapeutics filed for an IPO Thursday night, making it the sixth biotech in line this year for a potential listing on the Nasdaq. The San Diego biotech is trying to ...
View ArticleALX Oncology to make case for accelerated approval with evorpacept in gastric...
ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential accelerated approval pathway for its CD47-targeting drug in gastric cancer...
View ArticleModerna information chief to retire next month; Pharming looks to Flagship...
Moderna’s chief information officer Brad Miller is “retiring” in February, a company spokesperson confirmed to Endpoints News. His roughly two-year stint followed more than five years in top executive...
View ArticleNovo Nordisk’s amycretin prompts 22% weight loss in early obesity trial
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company said Friday. The data are highly competitive ...
View ArticleAstraZeneca allocates $570M for Canadian expansion, looks to add 700 new jobs
AstraZeneca is looking to increase its presence north of the US border. The UK pharma said it is budgeting $570 million to expand its footprint in Canada, which will help create more than 700 new ...
View ArticleBoehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off...
Plus, news about Madrona and Abdera: Boehringer Ingelheim combines two cancer units: The drugmaker is merging its cancer vaccine unit AMAL Therapeutics and its oncolytic virus team ViraTherapeutics,...
View ArticleThe crucial obesity data to watch for this year
This year has already started strong for obesity drug developers, with Novo Nordisk, Metsera and Hengrui/Kailera all proclaiming clinical successes for GLP-1-based drugs. What might the rest of 2025...
View ArticleTakeda discontinues US supply of gout drug Uloric
Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic versions, the company confirmed to Endpoints News. “We have taken this decision...
View ArticleUpcoming PDUFA dates may be ensnared by Trump's pause at HHS, analyst says
President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval decisions to later dates, a Raymond James analyst told investors on Thursday....
View ArticleMerck and Eisai reveal late-stage fail for Keytruda and Lenvima in...
The combination of Merck’s Keytruda and Eisai’s Lenvima failed to prolong patients’ lives versus the comparator in another cancer study, but the companies say they are committed to the approach. In the...
View ArticleWith Sam Altman’s help, Retro Biosciences eyes $1B to extend lifespan by 10...
Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed in a Friday email to Endpoints News. It would be one of the largest funding...
View ArticleBiogen paring back research efforts; Will Chinese biotechs threaten US...
Welcome to the weekend! We saw a flurry of health-related news from Washington DC this week as the Trump administration officially began its transition. Let’s go over it. On the day he was sworn into ...
View ArticleAgenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data
Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential pharma partners to chart a more conventional registrational path for its...
View ArticleAurion Biotech files for IPO amid legal battle with Alcon
Investors typically celebrate IPOs as milestone moments — and potential exit opportunities — for their startups. In an unusual twist, the eye giant Alcon has taken a different view, suing a startup it...
View ArticleAllakos restructures after Phase 1 failure; AB2 inks deal with Nippon Shinyaku
Plus, news about GSK: Allakos reports Phase 1 failure, lays off 75% of staff: The biotech said AK006 did not produce a clinical benefit in patients with chronic spontaneous urticaria, a ...
View ArticleVeru's drug lessens loss of lean mass in patients taking Wegovy
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors didn’t celebrate. The Miami biotech on Monday reported new Phase 2b data for ...
View ArticleTrump healthcare transition: Live updates, biotech, pharma news
It’s been one week since President Donald Trump returned to the Oval Office. We've already seen a flood of executive orders, and the pause on health agency communications has created a bit of a frenzy ...
View Article#ASCOGI25: Bristol Myers shares IO combo data in colorectal cancer; Pfizer...
Several drugmakers shared new clinical data at this year’s ASCO GI Symposium in San Francisco, and Endpoints News has rounded up a handful of notable presentations from Bristol Myers Squibb, Pfizer,...
View ArticleSage rejects Biogen’s deal offer, will look at other options
Sage Therapeutics knows it needs to do something. But it doesn't want to sell to its partner Biogen. On Monday, the troubled biotech said its board had unanimously rejected Biogen's ...
View ArticlePfizer inks $60M settlement to close Nurtec anti-kickback suit
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT. A Pfizer spokesperson said the company has...
View Article